AlainAlgaziMD

Oncology • San Francisco, CA

Assistant Professor, Medicine, University of California, San Francisco, School of

Join to view full profile

Dr. Algazi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Algazi's full profile

Already have an account?

Office
505 Parnassus Ave # M1286
Box 1270
San Francisco, CA 94143
Phone+1 415-476-0624

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2007 - 2010
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2004 - 2007
David Geffen School of Medicine at UCLAClass of 2004

Certifications & Licensure

CA State Medical License 2006 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma Start of enrollment: 2012 Jun 09
Completed
Phase 1, Phase 2
Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets Start of enrollment: 2013 Apr 01
Terminated
Phase 2
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma Start of enrollment: 2013 May 01
Completed
Phase 2
Trametinib With GSK2141795 in BRAF Wild-type Melanoma Start of enrollment: 2013 Sep 10
Completed
Phase 2
Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Sep 19
Active, not recruiting
Phase 2
Trial of pIL-12/MK-3475 in Metastatic Melanoma Start of enrollment: 2015 Aug 17
Completed
Phase 2
Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck Start of enrollment: 2016 Jul 06
Active, not recruiting
Phase 2
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2019 Mar 08
Recruiting
Phase 2
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2021 Aug 09
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

113 citations
Dynamic CD8T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes.
Maha K Rahim, Trine Line H Okholm, Kyle B Jones, Elizabeth E McCarthy, Candace C Liu
Cell. 2023-03-16
130 citations
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study
Roger B. Cohen, Jean Pierre Delord, Toshihiko Doi, Sarina Anne Piha-Paul, Stephen V. Liu
American Journal of Clinical Oncology. 2018-11-01
966 citations
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, p...
Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau, José Dinis, Lisa Licitra
Lancet. 2019-01-12

Journal Articles

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Kim Margolin, Alain Algazi, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igo..., The New England Journal of Medicine

Press Mentions

Leaving Lymph Nodes Intact Could Increase Efficacy of Cancer ImmunotherapyApril 12th, 2023
Sequential-Combinatorial Regimens Can Make Treatment More Effective for People with Aggressive CancersAugust 12th, 2021
Sensei Biotherapeutics Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and NeckMay 19th, 2021
Join now to see all